Immunotherapy before chemo: a new hope for Triple-Negative breast cancer?
NCT ID NCT04770272
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested whether giving the immunotherapy drug atezolizumab (Tecentriq) alone for two weeks before starting standard chemotherapy could improve outcomes for people with triple-negative breast cancer. The study enrolled 442 participants and compared the two-week window approach to starting atezolizumab and chemo together from the start. The main goal was to see if the window led to a higher rate of complete cancer disappearance by the time of surgery. The trial was terminated early, so final results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (Tecentriq) plus chemotherapy (carboplatin, paclitaxel, epirubicin, cyclophosphamide)
What this could lead to
If successful, this approach could improve the chance of eliminating all cancer before surgery in triple-negative breast cancer patients.
What could go wrong
The trial was terminated early, so results are limited. Adding immunotherapy may increase side effects without clear benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Marienhospital Bottrop gGmbH; Klinik für Frauenheilkunde und Geburtshilfe;
Bottrop, 46236, Germany